Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 15/20 | 0.67 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6308930 | 0.90 | MAPT (0.55) | CCR2HPGDSMN1; SMN2L3MBTL1KMT2A | |
| SCHEMBL6357264 | 0.90 | CCR2 (0.65) | CCR2ABCB11KMT2AMAPT | |
| SCHEMBL6308907 | 0.88 | MAPT (0.59) | CCR2HPGDSMN1; SMN2L3MBTL1KMT2A | |
| SCHEMBL7234016 | 0.88 | MAPT (0.55) | CCR2HPGDSMN1; SMN2L3MBTL1KMT2A | |
| SCHEMBL6599157 | 0.87 | CCR2 (0.66) | CCR2ABCB11KMT2AMAPT | |
| SCHEMBL6596843 | 0.86 | CCR2 (0.65) | CCR2ABCB11KMT2AMAPT | |
| SCHEMBL6307047 | 0.85 | HPGD (0.48) | CCR2HPGDSMN1; SMN2L3MBTL1KMT2A | |
| SCHEMBL6598129 | 0.85 | CCR2 (0.64) | CCR2ABCB11KMT2AMAPT | |
| SCHEMBL6598132 | 0.85 | CCR2 (0.64) | CCR2ABCB11KMT2AMAPT | |
| SCHEMBL6591932 | 0.85 | CCR2 (0.64) | CCR2ABCB11KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6953809-B2 | Monocyte chemoattractant protein-1 inhibitor compounds | ZENECA LIMITED (GB) | 2005-10-11 | — | — | US | disclosed |
| EP-1003504-B1 | INDOLE DERIVATIVES AND THEIR USE AS MCP-1 ANTAGONISTS | ASTRAZENECA AB (SE) | 2003-07-02 | — | — | EP | disclosed |
| US-20030119830-A1 | Monocyte chemoattractant protein-1 inhibitor compounds | ZENECA LIMITED | 2003-06-26 | — | — | US | disclosed |
| US-6569888-B1 | Such as ethyl-N-(dichlorobenzyl)-4-(3-hydroxypropylthio) indole-2-carboxylate; for treatment of arthritis | ASTRAZENECA AB (SE) | 2003-05-27 | — | — | US | disclosed |
| US-6441004-B1 | INDOLE DERIVATIVES AS ANTIINFLAMMATORY AGENTS | ZENECA LIMITED (GB) | 2002-08-27 | — | — | US | disclosed |
| EP-1150954-A1 | ANTI-IMFLAMMATORY INDOLE DERIVATIVES | AstraZeneca AB (SE) | 2001-11-07 | — | — | EP | disclosed |
| WO-2000046198-A1 | ANTI-INFLAMMATORY INDOLE DERIVATIVES | ASTRAZENECA AB (SE) | 2000-08-10 | — | — | WO | disclosed |
| EP-1003504-A2 | INDOLE DERIVATIVES AND THEIR USE AS MCP-1 ANTAGONISTS | AstraZeneca UK Limited (GB) | 2000-05-31 | — | — | EP | disclosed |
| WO-1999007351-A2 | INDOLE DERIVATIVES AND THEIR USE AS MCP-1 ANTAGONISTS | ZENECA LIMITED (GB) | 1999-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030119830-A1 | Monocyte chemoattractant protein-1 inhibitor compounds | CCL2, CCL11, CCR1 | CCR2 4/4885ABCB11 506/4885HPGD 1094/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.